Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Robert Thomas Freeman Sells 4,299 Shares

Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Robert Thomas Freeman sold 4,299 shares of Alignment Healthcare stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $4.84, for a total transaction of $20,807.16. Following the sale, the chief financial officer now owns 865,407 shares of the company’s stock, valued at $4,188,569.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Robert Thomas Freeman also recently made the following trade(s):

• On Tuesday, March 19th, Robert Thomas Freeman sold 28,522 shares of Alignment Healthcare stock. The stock was sold at an average price of $5.05, for a total transaction of $144,036.10.
• On Friday, March 15th, Robert Thomas Freeman sold 11,858 shares of Alignment Healthcare stock. The shares were sold at an average price of $4.89, for a total transaction of $57,985.62.

Alignment Healthcare Price Performance

Shares of ALHC stock traded up $0.17 on Friday, reaching $4.96. 780,532 shares of the company were exchanged, compared to its average volume of 1,199,306. Alignment Healthcare, Inc. has a 1 year low of $4.48 and a 1 year high of $9.20. The company has a market cap of $937.34 million, a price-to-earnings ratio of -6.28 and a beta of 1.34. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.84 and a current ratio of 1.84. The business has a 50-day moving average price of $6.00 and a 200 day moving average price of $6.84.

Alignment Healthcare (NASDAQ:ALHC) last posted its earnings results on Tuesday, February 27th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.03). The firm had revenue of $465.39 million during the quarter, compared to analyst estimates of $444.56 million. Alignment Healthcare had a negative net margin of 8.12% and a negative return on equity of 75.64%. The business’s revenue for the quarter was up 28.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.31) earnings per share. Equities research analysts forecast that Alignment Healthcare, Inc. will post -0.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alignment Healthcare

Several large investors have recently made changes to their positions in the stock. Durable Capital Partners LP lifted its holdings in Alignment Healthcare by 2,079.2% during the 1st quarter. Durable Capital Partners LP now owns 5,908,220 shares of the company’s stock worth $66,349,000 after buying an additional 5,637,102 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Alignment Healthcare by 25.1% during the 3rd quarter. Vanguard Group Inc. now owns 8,117,393 shares of the company’s stock worth $96,111,000 after buying an additional 1,626,831 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in Alignment Healthcare by 15.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 8,470,181 shares of the company’s stock worth $99,610,000 after buying an additional 1,108,973 shares in the last quarter. BlackRock Inc. lifted its holdings in Alignment Healthcare by 21.8% during the 3rd quarter. BlackRock Inc. now owns 5,698,621 shares of the company’s stock worth $67,471,000 after buying an additional 1,020,637 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Alignment Healthcare in the 4th quarter valued at approximately $11,601,000. 86.19% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently issued reports on ALHC shares. William Blair restated an “outperform” rating on shares of Alignment Healthcare in a research report on Wednesday, March 6th. Stephens boosted their target price on shares of Alignment Healthcare from $10.00 to $10.50 and gave the company an “equal weight” rating in a research report on Tuesday, January 9th. Raymond James upped their price objective on shares of Alignment Healthcare from $10.00 to $12.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 9th. Piper Sandler reiterated a “neutral” rating and issued a $6.00 price objective (down previously from $12.00) on shares of Alignment Healthcare in a research report on Wednesday, March 6th. Finally, UBS Group decreased their price objective on shares of Alignment Healthcare from $9.00 to $8.50 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Alignment Healthcare presently has an average rating of “Moderate Buy” and a consensus price target of $9.61.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.